SERAVUE
LIVE

Serial Number

50090913

Owner

ImCare Biotech, Inc.

Attorney

Mike McArthur

Filing Date

Sep 4, 2026

Add to watchlist:

No watchlists yet
View on USPTO

SERAVUE Trademark

Serial Number: 50090913

SERAVUE is a trademark filed by ImCare Biotech, Inc. on September 4, 2026. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

ImCare Biotech, Inc.

3805 Old Easton Road
Doylestown, PA 18902

Entity Type: 03

Trademark Details

Filing Date

September 4, 2026

Registration Date

Not Registered

Goods & Services

Downloadable computer software for use in medical diagnostics; Downloadable computer software for analyzing medical data; Downloadable medical software for analysis and interpretation of clinical diagnostic data; Downloadable medical software for analyzing biomarker data for use in medical diagnostics; Downloadable medical software for generating diagnostic reports; Downloadable computer application software for mobile phones and tablet computers, namely, software for integration, analysis, management, and exchange of clinical laboratory and diagnostic data, calculating diagnostic risk scores, longitudinal tracking of patient clinical data, and generating diagnostic reports; Downloadable software in the nature of a mobile application for integration, analysis, management, and exchange of clinical laboratory and diagnostic data, calculating diagnostic risk scores, longitudinal tracking of patient clinical data, and generating diagnostic reports

Software as a service (SAAS) services featuring software for analysis and interpretation of clinical diagnostic data; Software as a service (SAAS) services featuring software for calculating diagnostic risk scores; Software as a service (SAAS) services featuring software for statistical analysis of clinical diagnostic data; Software as a service (SAAS) services featuring software for longitudinal tracking and analysis of patient clinical data; Software as a service (SAAS) services featuring software for generating diagnostic reports; Software as a service (SAAS) services featuring software for integration, transmission, and exchange of clinical laboratory and diagnostic data; Providing on-line non-downloadable software using artificial intelligence (AI) for analysis and interpretation of clinical diagnostic data and diagnostic risk scores

Diagnostic reagents for medical use in in vitro diagnosis; Medical diagnostic reagents for use in in vitro diagnosis of liver cancer; Medical diagnostic reagents for use in detection and surveillance of liver cancer; Diagnostic biomarker reagents for medical purposes; Diagnostic reagents for medical use; Diagnostic test reagents for medical use; Diagnostic reagents for medical purposes; Diagnostic test reagents for medical purposes; Reagents for use in diagnostic tests for medical purposes; Biological reagents for medical purposes; Diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection, namely, liver cancer; Diagnostic kits comprising diagnostic agents, preparations and substances for medical use; Diagnostic agents, preparations and substances for medical purposes; Clinical medical reagents; Medical diagnostic reagents; Diagnostic chemical reagents for medical purposes; Chemical reagents for medical purposes

Filing History

APPLICATION FILING RECEIPT MAILED
Sep 4, 2026 MAFR
NEW APPLICATION ENTERED
Sep 4, 2026 NWAP